Table 1.

Suppression of tumor growth by AFL4 treatment

Antibodies μg/dose Tumor volume (mm3)‡
C6 tumor* 
 PBS  —  982 ± 246  
 Avas12† 600 1027 ± 137  
 AFL4  200  488 ± 58.51-153 
 600 296 ± 67.01-153 
 1000  312 ± 38.41-153 
PC-3 tumor 
 Avas12† 600  291 ± 90.1  
 AFL4  600 Not detectable 
Antibodies μg/dose Tumor volume (mm3)‡
C6 tumor* 
 PBS  —  982 ± 246  
 Avas12† 600 1027 ± 137  
 AFL4  200  488 ± 58.51-153 
 600 296 ± 67.01-153 
 1000  312 ± 38.41-153 
PC-3 tumor 
 Avas12† 600  291 ± 90.1  
 AFL4  600 Not detectable 

Experimental procedures were as described in Figure 4.

*

Results using the C6 glioblastoma cell line are the same as those presented in Figure 4.

†

AVAS12 is a nonblocking mAb to mVEGFR-2.

‡

Each value represents mean ± SEM of 8 mice for the PBS-treated group and 4 mice for other groups.

F1-153

P < .01.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal